Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
University of Pittsburgh
Hummingbird Bioscience
Boehringer Ingelheim
National Cancer Institute (NCI)
AVEO Pharmaceuticals, Inc.
Fate Therapeutics
NRG Oncology
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Pfizer
Erasca, Inc.
Centre Oscar Lambret
Wake Forest University Health Sciences
University of Texas Southwestern Medical Center
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Vanderbilt-Ingram Cancer Center
R-Pharm
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Tizona Therapeutics, Inc
National Cancer Institute (NCI)
Yale University
University of California, San Diego
Boehringer Ingelheim
Shanghai Institute Of Biological Products
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Washington University School of Medicine
Brown University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
University of Chicago
Pfizer
Servier
Centre Leon Berard
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center